We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+22.98%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.69B
AUM Growth
+$481M
Cap. Flow
+$129M
Cap. Flow %
4.79%
Top 10 Hldgs %
44.27%
Holding
113
New
25
Increased
16
Reduced
30
Closed
12

Top Buys

Rank Stock Value
1
KO icon
Coca-Cola
KO
+$32.8M
2
AAPL icon
Apple
AAPL
+$32.1M
3
AVBP icon
ArriVent BioPharma
AVBP
+$31.5M
4
ARGX icon
argenx
ARGX
+$26.4M
5
CRH icon
CRH
CRH
+$25.7M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$55.4M
2
RPRX icon
Royalty Pharma
RPRX
+$48.3M
3
LVS icon
Las Vegas Sands
LVS
+$36.3M
4
MSFT icon
Microsoft
MSFT
+$33.4M
5
TERN
Terns Pharmaceuticals
TERN
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 57.97%
2 Technology 7.85%
3 Communication Services 7.05%
4 Consumer Discretionary 4.46%
5 Financials 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTX icon
51
Immatics
IMTX
$1.32B
$9.95M 0.37%
+946,563
New +$11M
TERN
52
DELISTED
Terns Pharmaceuticals
TERN
$8.95M 0.33%
1,363,675
-4,473,451
-77% -$29.2M
IFRX icon
53
InflaRx
IFRX
$271M
$8.83M 0.33%
5,733,910
– –
ELAN icon
54
Elanco Animal Health
ELAN
$11.1B
$8.26M 0.31%
507,200
-107,100
-17% -$1.67M
RVNC
55
DELISTED
Revance Therapeutics, Inc.
RVNC
$7.87M 0.29%
+1,600,000
New +$9.47M
UNH icon
56
UnitedHealth
UNH
$370B
$7.48M 0.28%
15,123
+2,300
+18% +$1.17M
ZURA icon
57
Zura Bio
ZURA
$566M
$7.32M 0.27%
2,850,000
– –
GEHC icon
58
GE HealthCare
GEHC
$32.4B
$6.82M 0.25%
+75,000
New +$6.24M
KRRO icon
59
Korro Bio
KRRO
$195M
$6.64M 0.25%
73,821
– –
KZR
60
DELISTED
Kezar Life Sciences
KZR
$6.46M 0.24%
716,759
– –
PROK icon
61
ProKidney
PROK
$337M
$6.34M 0.24%
3,867,847
– –
SYRE icon
62
Spyre Therapeutics
SYRE
$9.25B
$6.16M 0.23%
162,395
– –
ALNY icon
63
Alnylam Pharmaceuticals
ALNY
$29.3B
$4.88M 0.18%
32,660
+22,800
+231% +$3.8M
TMO icon
64
Thermo Fisher Scientific
TMO
$220B
$4.22M 0.16%
7,260
– –
DHR icon
65
Danaher
DHR
$144B
$4.1M 0.15%
16,427
– –
ABT icon
66
Abbott
ABT
$187B
$3.81M 0.14%
33,520
– –
TEVA icon
67
Teva Pharmaceuticals
TEVA
$41.2B
$3.78M 0.14%
268,100
-229,300
-46% -$2.89M
GILD icon
68
Gilead Sciences
GILD
$165B
$3.71M 0.14%
50,700
+28,000
+123% +$2.15M
KVUE icon
69
Kenvue
KVUE
$36.9B
$3.68M 0.14%
171,596
– –
COR icon
70
Cencora
COR
$61.2B
$3.03M 0.11%
12,488
– –
TRML
71
DELISTED
Tourmaline Bio
TRML
$2.86M 0.11%
+125,000
New +$4.41M
MTD icon
72
Mettler-Toledo International
MTD
$28.6B
$2.61M 0.1%
+1,964
New +$2.42M
NTRA icon
73
Natera
NTRA
$46.4B
$2.25M 0.08%
24,600
– –
COGT icon
74
Cogent Biosciences
COGT
$7.24B
$2.12M 0.08%
316,000
-3,394,539
-91% -$21M
ISRG icon
75
Intuitive Surgical
ISRG
$134B
$2.08M 0.08%
5,200
+2,130
+69% +$805K
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Suvretta Capital Management held 113 positions worth $2.69B, up 22% from $2.21B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Suvretta Capital Management deployed $129M of net new capital in Q1 2024, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Coca-Cola: 546,500 shares worth $33.4M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 68% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Arcellx, an estimated $55.4M trimmed.

  • Suvretta Capital Management's largest Q1 2024 buy was Coca-Cola: 546,500 shares worth $33.4M.
  • Suvretta Capital Management added most to argenx in Q1 2024, an estimated $26.4M increase.
  • Suvretta Capital Management's biggest Q1 2024 reduction was Arcellx, cutting an estimated $55.4M.
  • Suvretta Capital Management fully exited Las Vegas Sands in Q1 2024, selling an estimated $36.3M.
  • Suvretta Capital Management's ten largest holdings make up 44% of its $2.69B portfolio in Q1 2024.
  • Suvretta Capital Management opened 25 new positions and closed 12 in Q1 2024.
  • Suvretta Capital Management's portfolio value rose 22% quarter-over-quarter to $2.69B.

Based on Suvretta Capital Management's 13F filing for Q1 2024, filed 15 May 2024.